- |||||||||| Trial primary completion date, Metastases: Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer (clinicaltrials.gov) - Dec 23, 2015
P2, N=330, Active, not recruiting,
Trial primary completion date: Jan 2016 --> Jun 2016 Trial primary completion date: Jan 2016 --> Jul 2016
- |||||||||| Hadlima (adalimumab-bwwd) / Organon, Biogen, Samsung, Mundipharma, Yuhan Corp
Trial initiation date: Pharmacokinetics, Safety, and Tolerability Study of the Pen and PFS of SB5 in Healthy Subjects (clinicaltrials.gov) - Dec 16, 2015
P1, N=190, Completed,
Trial primary completion date: Jan 2016 --> Jul 2016 Initiation date: Mar 2015 --> Jun 2015
- |||||||||| Lantus (insulin glargine) / Sanofi, Lusduna (insulin glargine biosimilar) / Samsung
Trial completion, Enrollment change: A Study of the Safety and Efficacy of MK-1293 Compared to Lantus (clinicaltrials.gov) - Dec 14, 2015
P3, N=730, Completed,
Initiation date: Mar 2015 --> Jun 2015 Active, not recruiting --> Completed | N=500 --> 730
- |||||||||| Eticovo (etanercept biosimilar) / Samsung, Merck (MSD), Ewopharma, Yuhan Corp, Mundipharma, Biogen
Clinical: A Study Comparing SB4 to Enbrel® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy (clinicaltrials.gov) - Dec 6, 2015
P3, N=596, Completed,
Active, not recruiting --> Completed | N=500 --> 730 Active, not recruiting --> Completed | Trial primary completion date: Nov 2014 --> Apr 2014
- |||||||||| Hadlima (adalimumab-bwwd) / Organon, Biogen, Samsung, Mundipharma, Yuhan Corp
Trial completion: A Study Comparing SB5 to Humira (clinicaltrials.gov) - Dec 5, 2015
P3, N=544, Completed,
Active, not recruiting --> Completed | Trial primary completion date: Nov 2014 --> Apr 2014 Active, not recruiting --> Completed
- |||||||||| Hadlima (adalimumab-bwwd) / Organon, Biogen, Samsung, Mundipharma, Yuhan Corp
Enrollment closed: An Multicentre Clinical Study to Evaluate the Usability and Safety of the Pre-filled Pen and Pre-filled Syringe of SB5 in Subjects With Rheumatoid Arthritis (clinicaltrials.gov) - Dec 5, 2015
P2, N=50, Active, not recruiting,
Trial primary completion date: Dec 2015 --> Mar 2016 Recruiting --> Active, not recruiting
- |||||||||| Renflexis (infliximab-abda) / Yuhan Corp, Biogen, Ewopharma, Samsung, Organon
Trial completion: A Study Comparing SB2 to Remicade (clinicaltrials.gov) - Dec 4, 2015
P3, N=584, Completed,
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- |||||||||| Aybintio (bevacizumab biosimilar) / Samsung, Mundipharma
Clinical: Pharmacokinetic, Safety, Tolerability, and Immunogenicity Study of SB8 in Healthy Male Subjects (clinicaltrials.gov) - Nov 27, 2015
P1, N=119, Completed,
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Dec 2015 --> Sep 2015
- |||||||||| Hadlima (adalimumab-bwwd) / Organon, Biogen, Samsung, Mundipharma, Yuhan Corp
Trial completion, Enrollment change, Trial primary completion date: Pharmacokinetics, Safety, and Tolerability Study of the Pen and PFS of SB5 in Healthy Subjects (clinicaltrials.gov) - Nov 27, 2015
P1, N=190, Completed,
Active, not recruiting --> Completed | Trial primary completion date: Dec 2015 --> Sep 2015 Active, not recruiting --> Completed | N=250 --> 190 | Trial primary completion date: Jan 2016 --> Sep 2015
- |||||||||| Lantus (insulin glargine) / Sanofi, Lusduna (insulin glargine biosimilar) / Samsung
Trial initiation date: A Study of the Safety and Efficacy of MK-1293 Compared to Lantus (clinicaltrials.gov) - Nov 5, 2015
P3, N=500, Active, not recruiting,
Active, not recruiting --> Completed | N=250 --> 190 | Trial primary completion date: Jan 2016 --> Sep 2015 Initiation date: Feb 2014 --> Oct 2013
- |||||||||| Hadlima (adalimumab-bwwd) / Organon, Biogen, Samsung, Mundipharma, Yuhan Corp
Enrollment closed, Trial primary completion date: Pharmacokinetics, Safety, and Tolerability Study of the Pen and PFS of SB5 in Healthy Subjects (clinicaltrials.gov) - Oct 27, 2015
P1, N=250, Active, not recruiting,
Initiation date: Feb 2014 --> Oct 2013 Not yet recruiting --> Active, not recruiting | Trial primary completion date: Aug 2015 --> Jan 2016
- |||||||||| Vegzelma (bevacizumab-adcd) / Celltrion, Avastin (bevacizumab) / Roche, Avzivi (bevacizumab-tnjn) - Bio / Thera Solutions, Cipla, BeiGene, Biomm, Mega Lifesciences, Sandoz
Trial completion, Trial primary completion date, Surgery: CALGB 40603: Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery (clinicaltrials.gov) - Oct 19, 2015
P2, N=454, Completed,
Not yet recruiting --> Active, not recruiting | Trial primary completion date: Aug 2015 --> Jan 2016 Active, not recruiting --> Completed | Trial primary completion date: Aug 2013 --> Aug 2014
- |||||||||| Aybintio (bevacizumab biosimilar) / Samsung, Mundipharma
Clinical: Pharmacokinetic, Safety, Tolerability, and Immunogenicity Study of SB8 in Healthy Male Subjects (clinicaltrials.gov) - Sep 28, 2015
P1, N=114, Active, not recruiting,
Active, not recruiting --> Completed | Trial primary completion date: Aug 2013 --> Aug 2014 Not yet recruiting --> Active, not recruiting | Trial primary completion date: Sep 2015 --> Dec 2015
- |||||||||| Ontruzant (trastuzumab-dttb) / Samsung, AffaMed Therap, Mundipharma, Organon
Enrollment closed, Metastases: A Study to Compare the Effect of SB3 and Herceptin (clinicaltrials.gov) - Sep 24, 2015
P3, N=806, Active, not recruiting,
Not yet recruiting --> Active, not recruiting | Trial primary completion date: Sep 2015 --> Dec 2015 Recruiting --> Active, not recruiting
- |||||||||| Vegzelma (bevacizumab-adcd) / Celltrion, Avastin (bevacizumab) / Roche, Avzivi (bevacizumab-tnjn) - Bio / Thera Solutions, Cipla, BeiGene, Biomm, Mega Lifesciences, Sandoz
Trial primary completion date, Combination therapy, Metastases: Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer (clinicaltrials.gov) - Aug 13, 2015
P3, N=650, Active, not recruiting,
Trial primary completion date: Jul 2015 --> Jan 2016 Trial primary completion date: Dec 2014 --> Dec 2015
- |||||||||| Trial primary completion date, Metastases: Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer (clinicaltrials.gov) - Aug 13, 2015
P2, N=330, Active, not recruiting,
Trial primary completion date: Dec 2014 --> Dec 2015 Trial primary completion date: Jan 2015 --> Jan 2016
- |||||||||| Lantus (insulin glargine) / Sanofi, Lusduna (insulin glargine biosimilar) / Samsung
Trial primary completion date: A Study of the Safety and Efficacy of MK-1293 Compared to Lantus (clinicaltrials.gov) - Jul 14, 2015
P3, N=500, Active, not recruiting,
Trial primary completion date: Jan 2015 --> Jan 2016 Trial primary completion date: May 2015 --> Nov 2015
- |||||||||| Renflexis (infliximab-abda) / Yuhan Corp, Biogen, Ewopharma, Samsung, Organon
Trial primary completion date: A Study Comparing SB2 to Remicade (clinicaltrials.gov) - Jun 11, 2015
P3, N=584, Active, not recruiting,
Trial primary completion date: Aug 2015 --> Dec 2015 Trial primary completion date: Aug 2014 --> Nov 2014
- |||||||||| Vegzelma (bevacizumab-adcd) / Celltrion, Avastin (bevacizumab) / Roche, Avzivi (bevacizumab-tnjn) - Bio / Thera Solutions, Cipla, BeiGene, Biomm, Mega Lifesciences, Sandoz
Trial initiation date: ECOG-ACRIN 5103: Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer (clinicaltrials.gov) - Jun 11, 2015
P3, N=4950, Active, not recruiting,
Trial primary completion date: Aug 2014 --> Nov 2014 Initiation date: Nov 2007 --> Dec 2009
- |||||||||| Eticovo (etanercept biosimilar) / Samsung, Merck (MSD), Ewopharma, Yuhan Corp, Mundipharma, Biogen
Clinical: A Study Comparing SB4 to Enbrel® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy (clinicaltrials.gov) - Apr 14, 2015
P3, N=498, Active, not recruiting,
Active, not recruiting --> Completed | N=130 --> 76 Trial primary completion date: Jun 2014 --> Nov 2014
- |||||||||| Lantus (insulin glargine) / Sanofi, Lusduna (insulin glargine biosimilar) / Samsung
Trial completion: The Safety and Efficacy of MK-1293 Versus Lantus (clinicaltrials.gov) - Apr 3, 2015
P3, N=528, Completed,
Trial primary completion date: Jun 2014 --> Nov 2014 Active, not recruiting --> Completed
- |||||||||| Lusduna (insulin glargine biosimilar) / Samsung
Enrollment closed: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-1293 Compared With a Basal Insulin in Participants With Type 1 Diabetes (MK-1293-005) (clinicaltrials.gov) - Mar 19, 2015
P1, N=130, Active, not recruiting,
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- |||||||||| Vegzelma (bevacizumab-adcd) / Celltrion, Avastin (bevacizumab) / Roche, Avzivi (bevacizumab-tnjn) - Bio / Thera Solutions, Cipla, BeiGene, Biomm, Mega Lifesciences, Sandoz
Enrollment closed, Metastases: Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov) - Mar 9, 2015
P3, N=400, Active, not recruiting,
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- |||||||||| Hadlima (adalimumab-bwwd) / Organon, Biogen, Samsung, Mundipharma, Yuhan Corp
New P1 trial: Pharmacokinetics, Safety, and Tolerability Study of the Pen and PFS of SB5 in Healthy Subjects (clinicaltrials.gov) - Dec 29, 2014
P1, N=250, Not yet recruiting,
- |||||||||| Hadlima (adalimumab-bwwd) / Organon, Biogen, Samsung, Mundipharma, Yuhan Corp
Enrollment closed: A Study Comparing SB5 to Humira (clinicaltrials.gov) - Dec 5, 2014
P3, N=490, Active, not recruiting,
Trial primary completion date: Nov 2014 --> Nov 2015 Recruiting --> Active, not recruiting
- |||||||||| Lantus (insulin glargine) / Sanofi, Lusduna (insulin glargine biosimilar) / Samsung
Enrollment closed: A Study of the Safety and Efficacy of MK-1293 Compared to Lantus (clinicaltrials.gov) - Nov 19, 2014
P3, N=500, Active, not recruiting,
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- |||||||||| Vegzelma (bevacizumab-adcd) / Celltrion, Avastin (bevacizumab) / Roche, Avzivi (bevacizumab-tnjn) - Bio / Thera Solutions, Cipla, BeiGene, Biomm, Mega Lifesciences, Sandoz
Enrollment closed: Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer (clinicaltrials.gov) - Oct 28, 2014
P3, N=332, Active, not recruiting,
Recruiting --> Active, not recruiting Suspended --> Active, not recruiting
- |||||||||| Lantus (insulin glargine) / Sanofi, Lusduna (insulin glargine biosimilar) / Samsung
Enrollment closed: The Safety and Efficacy of MK-1293 Versus Lantus (clinicaltrials.gov) - Oct 27, 2014
P3, N=500, Active, not recruiting,
Suspended --> Active, not recruiting Recruiting --> Active, not recruiting
- |||||||||| Hadlima (adalimumab-bwwd) / Organon, Biogen, Samsung, Mundipharma, Yuhan Corp
Trial completion: Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of SB5 in Healthy Subjects (clinicaltrials.gov) - Oct 15, 2014
P1, N=189, Completed,
Recruiting --> Active, not recruiting Recruiting --> Completed
- |||||||||| Vegzelma (bevacizumab-adcd) / Celltrion, Avastin (bevacizumab) / Roche, Avzivi (bevacizumab-tnjn) - Bio / Thera Solutions, Cipla, BeiGene, Biomm, Mega Lifesciences, Sandoz
Enrollment change, Surgery, Metastases: S0533: Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery (clinicaltrials.gov) - Sep 16, 2014
P=N/A, N=28, Active, not recruiting,
Recruiting --> Completed N=182 --> 28
- |||||||||| Vegzelma (bevacizumab-adcd) / Celltrion, Avastin (bevacizumab) / Roche, Avzivi (bevacizumab-tnjn) - Bio / Thera Solutions, Cipla, BeiGene, Biomm, Mega Lifesciences, Sandoz
Trial completion, Metastases: Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer (clinicaltrials.gov) - Sep 15, 2014
P3, N=394, Completed,
N=182 --> 28 Active, not recruiting --> Completed
- |||||||||| Vegzelma (bevacizumab-adcd) / Celltrion, Avastin (bevacizumab) / Roche, Avzivi (bevacizumab-tnjn) - Bio / Thera Solutions, Cipla, BeiGene, Biomm, Mega Lifesciences, Sandoz
Enrollment closed, Metastases: Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer (clinicaltrials.gov) - Sep 10, 2014
P3, N=394, Active, not recruiting,
Active, not recruiting --> Completed Completed --> Active, not recruiting
- |||||||||| Vegzelma (bevacizumab-adcd) / Celltrion, Avastin (bevacizumab) / Roche, Avzivi (bevacizumab-tnjn) - Bio / Thera Solutions, Cipla, BeiGene, Biomm, Mega Lifesciences, Sandoz
Trial completion, Enrollment change, Metastases: Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer (clinicaltrials.gov) - Jul 16, 2014
P3, N=394, Completed,
Initiation date: Sep 2013 --> Dec 2013 Active, not recruiting --> Completed | N=502 --> 394
|
